Skip to content

Riding the Wave | Differentiating Bispecifics and CAR-T for Relapsed Refractory Multiple Myeloma
Expert Consult #2: Eye on the Future in Multiple Myeloma
*Pre-assessment*

Before you view this Expert Consult video, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your credentials?(Required.)
2.What is your community of practice?
3.Compared to the phase 3 CARTITUDE-4 clinical trial, a key difference in demographics of patients enrolled in the phase 3 KarMMa-3 clinical trial is that more than half of patients had which of the following characteristics? (Required.)
4.The results of the phase 3 CARTITUDE-4 clinical trial demonstrated which of the following outcomes? (Required.)
5.Which of the following has been observed in approximately 50% to 70% of patients receiving investigational bi-/trispecific antibodies for relapsed/refractory multiple myeloma? (Required.)
6.All of the following are barriers to use of soluble BCMA as a biomarker in clinical practice EXCEPT?
7.Which of the following types of biomarkers is correctly matched to biomarker routinely used in the management of patients with multiple myeloma? 
8.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.
Privacy & Cookie Notice